Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770540 | 0.90 | MEN1 (0.40) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6770041 | 0.88 | CRHR1 (0.46) | CRHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL6775168 | 0.82 | CRHR1 (0.35) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6770805 | 0.82 | HTT (0.39) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL8112895 | 0.80 | CRHR1 (0.32) | CRHR1KDM4EALDH1A1TDP1EDNRB | |
| SCHEMBL6770815 | 0.72 | KMT2A (0.39) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6780139 | 0.71 | TSHR (0.40) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6770576 | 0.71 | KMT2A (0.39) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6780509 | 0.71 | MEN1 (0.39) | CRHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6781376 | 0.71 | MEN1 (0.39) | CRHR1KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | claimed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | claimed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | claimed |
| US-6818648-B2 | PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; EATING DISORDERS; ALCOHOLISM; DRUG ABUSE; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-11-16 | — | — | US | disclosed |
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | CRHR1 51/4885KDM4E 1989/4885MEN1 3005/4885 |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | CRHR1 53/4885KDM4E 2000/4885MEN1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.